Just today, Eli Lilly's drug Donanemab (Kisunla) was approved by the FDA as a means to slow the progression of Early-Onset Alzheimer's. This approval marks a critical milestone in the fight against a disease that has long avoided treatment.
Donanemab is the latest in a series of promising developments. It follows the approval of Lecanemab (Leqembi) by the FDA last year, another monoclonal antibody designed to slow the progression of Alzheimer's. Both Donanemab and Lecanemab target amyloid plaques, abnormal protein deposits in the brain that are characteristic of Alzheimer's disease. By addressing these plaques, these drugs aim to decelerate the cognitive decline associated with the condition.
Despite these advancements, Alzheimer's remains a major problem. Aside from being incurable, its prevalence continues to rise, expected to affect 14 million people by 2050. While new treatments offer hope and can improve quality of life by slowing disease progression, they aren't as effective as preventing the onset of the disease in the first place.
Through our risk assessments we seek to provide individuals with the information and lifestyle habits they need to either avoid the disease in the first place, or to get treatment as early as possible.